BJG-03-025
Modify Date: 2024-04-09 12:07:38
BJG-03-025 structure
|
Common Name | BJG-03-025 | ||
|---|---|---|---|---|
| CAS Number | 2553213-90-2 | Molecular Weight | 563.725 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C28H37N9O2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BJG-03-025BJG-03-025 is a potent, highly selective FAK tyrosine kinase inhibitor with biochemical IC50 of 20.2 nM.BJG-03-025 demonstrates excellent kinome selectivity was profiled by KINOMEscan screening, PLK1 proved to be a false positive with IC50 of 8.3 uM, 100-300-fold selective for FAK.BJG-03-025 displays antiproliferative activity in three-dimensional (3D)-breast and gastric cancer models and impacts cellular signaling and migration.BJG-03-025 decreased phosphorylated FAK (pFAK Y397) in gastric cancer CDH1–/–RHOAY42C/+ organoid model, decreased aberrant signaling and proliferation of gastric cancer organoids. |
| Name | BJG-03-025 |
|---|
| Description | BJG-03-025 is a potent, highly selective FAK tyrosine kinase inhibitor with biochemical IC50 of 20.2 nM.BJG-03-025 demonstrates excellent kinome selectivity was profiled by KINOMEscan screening, PLK1 proved to be a false positive with IC50 of 8.3 uM, 100-300-fold selective for FAK.BJG-03-025 displays antiproliferative activity in three-dimensional (3D)-breast and gastric cancer models and impacts cellular signaling and migration.BJG-03-025 decreased phosphorylated FAK (pFAK Y397) in gastric cancer CDH1–/–RHOAY42C/+ organoid model, decreased aberrant signaling and proliferation of gastric cancer organoids. |
|---|---|
| References | 1. Brian J Groendyke, et al. ACS Med Chem Lett. 2020 Dec 14;12(1):30-38. |
| Molecular Formula | C28H37N9O2S |
|---|---|
| Molecular Weight | 563.725 |